Premium
Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia
Author(s) -
Bowen A. L.,
Zomas A.,
Emmett E.,
Matutes E.,
Dyer M. J. S.,
Catovsky D.
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.d01-2061.x
Subject(s) - fludarabine , prolymphocytic leukemia , medicine , chronic lymphocytic leukemia , immunology , leukemia , chemotherapy , cyclophosphamide
Seven patients with B‐cell leukaemia — six with chronic lymphocytic leukaemia (CLL) and one with B‐prolymphocytic leukaemia (B‐PLL) — were treated with CAMPATH‐1H[Note 1. CAMPATH‐1H is a trademark owned by the Wellcome group ...], a genetically reshaped CD52 monoclonal antibody, administered subcutaneously (s.c.) three times a week for 6–12 weeks. Four were resistant to, and three had had a short partial remission (PR) following, fludarabine chemotherapy. The patient with B‐PLL achieved complete remission and three patients with CLL attained PR; two of the latter were retreated. The three remaining patients were non‐responders. Three patients were transfusion‐dependent before CAMPATH and all three became transfusion‐independent after treatment. The overall median survival from starting CAMPATH‐1H was 11 months. Three patients reactivated cytomegalovirus (CMV) during the course of treatment, and two were treated with, and responded to, ganciclovir.